Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cefazedone is a semisynthetic first-generation cephalosporin antibiotic belonging to the β-lactam class. It exhibits antibacterial activity against both Gram-positive and Gram-negative bacteria. The drug acts by binding to and inactivating penicillin-binding proteins (PBPs) located on the inner membrane of the bacterial cell wall. PBPs are enzymes involved in the final stages of assembling and reshaping the bacterial cell wall during growth and division. Inactivation of these proteins interferes with cross-linking of peptidoglycan chains, weakening cell wall strength and rigidity, ultimately leading to bacterial cell lysis[1][3][5][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cefazedone.